Advanced Oncotherapy (AVO)

Sector:

Health Care

 1.93p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 25.00
  • 52 Week Low: 1.75
  • Currency: UK Pounds
  • Shares Issued: 542.57m
  • Volume: 0
  • Market Cap: £10.44m

Advanced Oncotherapy subscription cash gets regulatory clearance

By Josh White

Date: Friday 16 Feb 2018

LONDON (ShareCast) - (ShareCast News) - Next-generation proton therapy systems developer Advanced Oncotherapy announced on Friday that, in relation to its announcement on 7 December and following the passing of the resolution by shareholders on 23 January, it has been informed by Yantai Cipu that the Chinese authorities have authorised the transfer from China of £13.5m.
The AIM-traded firm said the amount was payable by Yantai Cipu for the subscription for 45 million new ordinary shares, to be issued by the company to Yantai Cipu at 30p per share.

As a result of the subscription, and as detailed in a circular issued on 22 December, the placing of 10,868,782 new ordinary shares with new and existing investors at the subscription price, as well as the conversion of the loan made by Swedish investors by way of issue of 13,697,697 new ordinary shares, was also completed.

Application had been made for admission to trading on AIM of the 69,566,479 new ordinary shares deriving from the cubscription, the placing and the conversion, the board confirmed, with admission expected on or around 22 February.

Following admission, the total number of ordinary shares in issue would be 150,501,673, and Yantai Cipu would hold 29.90% of the enlarged issued share capital of the company.

"Yantai Cipu has also informed the company that they are in advanced negotiation with a major medical equipment and pharmaceutical distribution company in China for a collaboration to accelerate and strengthen their market access in the People's Republic of China, Hong Kong, Macau, Taiwan and South Korea," the board announced in its statement.

"The company and Yantai Cipu have agreed that it is in the best interest of the company and its shareholders to extend the long stop date for the distribution agreement until 31 March to enable the satisfactory completion of the negotiations with the new participant."

Advanced Oncotherapy said the commitment of Yantai Cipu around the distribution agreement remained unchanged, and the receipt of the £16.5m payment from Yantai Cipu relating to the commercial agreement with was not conditional on the completion of negotiations with the distribution company.

"The receipt of funds in relation to the commercial agreement is subject to approval from the Government of the People's Republic of China for the transfer of monies to the United Kingdom."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

AVO Market Data

Currency UK Pounds
Share Price 1.93p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 25.00
52 Week Low 1.75
Volume 0
Shares Issued 542.57m
Market Cap £10.44m

AVO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
74.4% below the market average74.4% below the market average74.4% below the market average74.4% below the market average74.4% below the market average
40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average40.54% below the sector average
Income Not Available
Growth Not Available

AVO Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

AVO Key Personnel

CEO Nicolas Serandour

Top of Page